Study of Escitalopram in the Treatment of Specific Phobia
NCT00121069 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2005-07-21
Summary
This pilot study is designed to assess the efficacy of escitalopram in the treatment of specific phobia in adult outpatients.
Conditions
- Phobic Disorders
Interventions
- DRUG
-
Escitalopram
Sponsors & Collaborators
-
Forest Laboratories
collaborator INDUSTRY -
Connor, Kathryn M., M.D.
lead INDIV
Principal Investigators
-
Kathryn M. Connor, M.D. · Duke University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2002-09-30
- Completion
- 2004-09-30
Countries
- United States
Study Locations
More Related Trials
-
St. John's Wort Versus Placebo in Social Phobia
NCT00035412 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
NCT02432703 ·Status: COMPLETED ·Phase: PHASE2
-
Cannabidiol Effects on Fear Extinction in Social Phobia
NCT06123702 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Generalized Fear Extinction to Untreated Fear Stimuli in Specific Phobias After Exposure
NCT03907345 ·Status: COMPLETED ·Phase: NA
-
Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder
NCT06693609 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder
NCT00438971 ·Status: COMPLETED ·Phase: PHASE4
-
Neurobiology of Generalized Fear-Conditioning & Avoidance in Anxiety Disorders
NCT03033056 ·Status: COMPLETED
-
Quetiapine in Social Anxiety Disorder
NCT00215254 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)
NCT00612859 ·Status: COMPLETED ·Phase: PHASE2
-
Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults
NCT00601965 ·Status: COMPLETED ·Phase: NA
-
A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms
NCT05407064 ·Status: COMPLETED ·Phase: PHASE2
-
Investigating the Effects of Cannabidiol on Social Anxiety Disorder
NCT05649059 ·Status: RECRUITING ·Phase: PHASE4
-
The Impact of Sex Hormones on One-session Treatment for Spider Phobia in Women
NCT02622087 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.
NCT00214994 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment for Specific Phobias in Children
NCT00051220 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
NCT03924323 ·Status: COMPLETED ·Phase: PHASE4
-
Escitalopram in Patients With Generalized Anxiety Disorder
NCT00902564 ·Status: COMPLETED ·Phase: PHASE4
-
A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder
NCT00390650 ·Status: COMPLETED ·Phase: PHASE3
-
Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety
NCT00920387 ·Status: COMPLETED ·Phase: PHASE2
-
Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects
NCT00616655 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Vilazodone to Treat Social Anxiety Disorder
NCT01712321 ·Status: UNKNOWN ·Phase: NA
-
Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)
NCT01100255 ·Status: COMPLETED ·Phase: PHASE2
-
Generalization of Extinction Learning
NCT01900301 ·Status: COMPLETED ·Phase: PHASE1
-
Duloxetine vs Placebo in the Treatment of General Anxiety
NCT00475969 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder
NCT00191022 ·Status: COMPLETED ·Phase: PHASE2